# VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

> **NCT03120624** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Endometrial Carcinoma
- Recurrent Endometrial Adenocarcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Mixed Cell Adenocarcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinosarcoma
- Stage IV Uterine Corpus Cancer AJCC v7

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Computed Tomography
- **OTHER:** Fluorine F 18 Tetrafluoroborate
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Technetium Tc-99m Sodium Pertechnetate
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT03120624
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-15
- **Primary completion:** 2023-08-29
- **Final completion:** 2028-01-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03120624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03120624, "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03120624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*